Story perspectives

Trump Administration Weighs 100% Tariff on Uncooperative Drugmakers

4/2/2026

Summary

Story summary

U.S. President Donald Trump’s administration is considering a 100% tariff on imported branded and patented medicines for drugmakers that lack agreements for low U.S. prices.
Plans are not finalized and may exempt certain medicines and disease categories.
Pfizer and AstraZeneca have multi-year tariff exemptions; Eli Lilly and Johnson & Johnson are investing billions to expand U.S. operations.
Companies without agreements may face the full tariff, affecting investment and access.

1 of 1

Story summary

U.S. President Donald Trump’s administration is considering a 100% tariff on imported branded and patented medicines for drugmakers that lack agreements for low U.S. prices.
Plans are not finalized and may exempt certain medicines and disease categories.
Pfizer and AstraZeneca have multi-year tariff exemptions; Eli Lilly and Johnson & Johnson are investing billions to expand U.S. operations.
Companies without agreements may face the full tariff, affecting investment and access.